161 related articles for article (PubMed ID: 12011757)
41. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
42. Jornay PM -- evening-dosed methylphenidate for ADHD.
Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
[No Abstract] [Full Text] [Related]
43. [Methylphenidate of retard forms in children and adolescents with ADHD - an overview].
Pelz R; Banaschewski T; Becker K
Klin Padiatr; 2008; 220(2):93-100. PubMed ID: 18157763
[TBL] [Abstract][Full Text] [Related]
44. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
45. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
[TBL] [Abstract][Full Text] [Related]
46. Methylphenidate isomer approved by FDA.
Am J Health Syst Pharm; 2002 Feb; 59(3):230, 232. PubMed ID: 11862632
[No Abstract] [Full Text] [Related]
47. Attention-deficit-hyperactivity disorder.
Diller LH
N Engl J Med; 1999 Jun; 340(22):1766; author reply 1767. PubMed ID: 10357639
[No Abstract] [Full Text] [Related]
48. Evidence and belief in attention deficit hyperactivity disorder. Reintroduction of methylphenidate in Italy needs careful monitoring.
Bonati M; Impicciatore P; Pandolfini C
BMJ; 2001 Mar; 322(7285):556. PubMed ID: 11263458
[No Abstract] [Full Text] [Related]
49. Methylphenidate.
St Dennis C; Synoground G
J Sch Nurs; 1996 Feb; 12(1):5-8, 10-1. PubMed ID: 8696016
[No Abstract] [Full Text] [Related]
50. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
Silva RR
Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
[No Abstract] [Full Text] [Related]
51. Drugs for ADHD.
Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
[No Abstract] [Full Text] [Related]
52. WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2016 May; (5):CD005041. PubMed ID: 27228176
[No Abstract] [Full Text] [Related]
53. FPIN's clinical inquiries: Management of ADHD in preschool-aged children.
Klein S; Ho V; Tazkarji B; Auten B
Am Fam Physician; 2013 Sep; 88(6):398-400. PubMed ID: 24134048
[No Abstract] [Full Text] [Related]
54. [Methylphenidate misuse].
Bruggisser M; Bodmer M; Liechti ME
Praxis (Bern 1994); 2012 Feb; 101(5):299-305. PubMed ID: 22377977
[TBL] [Abstract][Full Text] [Related]
55. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.
Connor DF; Steingard RJ
CNS Drugs; 2004; 18(14):1011-30. PubMed ID: 15584770
[TBL] [Abstract][Full Text] [Related]
56. Adults with ADHD: ignored and under-treated.
Drug and Therapeutics Bulletin
Drug Ther Bull; 2011 Jul; 49(7):73. PubMed ID: 21752832
[No Abstract] [Full Text] [Related]
57. Pharmacology of adult ADHD with stimulants.
Spencer TJ
CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
[No Abstract] [Full Text] [Related]
58. Stimulant medications: how to minimize their reinforcing effects?
Volkow ND
Am J Psychiatry; 2006 Mar; 163(3):359-61. PubMed ID: 16513852
[No Abstract] [Full Text] [Related]
59. Prescribing methylphenidate for moderate ADHD.
McClure I
BMJ; 2013 Oct; 347():f6216. PubMed ID: 24133145
[No Abstract] [Full Text] [Related]
60. Dexmethylphenidate.
Keating GM; Figgitt DP
Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
